Roche Holding AG

🇨🇭Switzerland

Country: 🇨🇭Switzerland

Ownership: Public

Established: 1896-01-15

Employees: 103.6K

Market Cap: $270.5B

Website: http://www.roche.com

Clinical Trials

An Observational, Prospective, Safety Study of Mircera (Monopegylated Epoetin Beta) in Clinical Practice

Completed

Conditions: Kidney Disease, Chronic

Interventions: Drug: Mircera

First Posted Date: 2014-10-13

Last Posted Date: 2016-09-07

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 748

Registration Number: NCT02263833

A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma

Phase 1

Completed

Conditions: Lymphoma

Interventions: Drug: Bendamustine
Drug: Obinutuzumab
Drug: Polatuzumab vedotin (Liquid)
Drug: Polatuzumab vedotin (Lyophilized)
Drug: Rituximab

First Posted Date: 2014-10-06

Last Posted Date: 2022-11-14

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 331

Registration Number: NCT02257567

Locations: 🇳🇱
UMC St. Radboud; Hematology, Nijmegen, Netherlands
🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸
Swedish Cancer Inst., Seattle, Washington, United States

and more 59 locations

A Study of RO5186582 Treatment on Cytochrome P450 (CYP) 3A4 Activity in Healthy Participants

Phase 1

Completed

Conditions: Healthy Volunteer

Interventions: Drug: RO5186582
Drug: Midazolam, oral
Drug: Midazolam, IV

First Posted Date: 2014-10-02

Last Posted Date: 2016-11-02

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 12

Registration Number: NCT02254759

Study of Tocilizumab (RoActemre) Administered Subcutaneously in Participants With Rheumatoid Arthritis in Everyday Clinical Practice

Completed

Conditions: Rheumatoid Arthritis

First Posted Date: 2014-09-29

Last Posted Date: 2020-09-22

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 1454

Registration Number: NCT02251860

Locations: 🇩🇪
CIRI - Centrum für Innovative Diagnostik und Therapie Rheumatologie/ Immunologie (GmbH), Frankfurt, Germany

A Study Investigating the Safety and Efficacy of Lampalizumab Intravitreal Injections in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration

Phase 3

Terminated

Conditions: Geographic Atrophy

Interventions: Other: Sham Comparator
Drug: Lampalizumab

First Posted Date: 2014-09-25

Last Posted Date: 2019-10-15

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 975

Registration Number: NCT02247531

Locations: 🇺🇸
Southern Vitreoretinal Assoc, Tallahassee, Florida, United States
🇺🇸
Retina Health Center, Fort Myers, Florida, United States
🇺🇸
Retina Consultants of Orange County, Fullerton, California, United States

and more 149 locations

A Study Investigating the Efficacy and Safety of Lampalizumab Intravitreal Injections in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration

Phase 3

Terminated

Conditions: Geographic Atrophy

Interventions: Drug: Lampalizumab
Other: Sham

First Posted Date: 2014-09-25

Last Posted Date: 2019-06-26

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 906

Registration Number: NCT02247479

Locations: 🇺🇸
Texas Retina Associates, Arlington, Texas, United States
🇺🇸
Orange County Retina Med Group, Santa Ana, California, United States
🇺🇸
Maine Eye Center, Portland, Maine, United States

and more 141 locations

Comparison of the Treatments of Obinutuzumab + Venetoclax Versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia

Phase 3

Active, not recruiting

Conditions: Lymphocytic Leukemia, Chronic

Interventions: Drug: Venetoclax
Drug: Chlorambucil
Drug: Obinutuzumab

First Posted Date: 2014-09-17

Last Posted Date: 2024-12-02

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 445

Registration Number: NCT02242942

Locations: 🇺🇸
Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
🇮🇹
Az. Osp. S. Maria; Dept. Di Oncologia Medica, Terni, Umbria, Italy
🇦🇹
Wilhelminenspital; I. Medizinische Abt., Wien, Austria

and more 134 locations

A Study of RO6885247 in Adult and Pediatric Patients With Spinal Muscular Atrophy (MOONFISH)

Phase 1

Terminated

Conditions: Muscular Atrophy, Spinal

Interventions: Drug: RO6885247
Drug: placebo

First Posted Date: 2014-09-15

Last Posted Date: 2016-12-22

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 9

Registration Number: NCT02240355

Locations: 🇫🇷
Ch Pitie Salpetriere; Institut de Myologie, Paris, France
🇸🇪
Drottning Silvias Barn- och ungdomssjukhus; Kliniken för barnmedicin, Goeteborg, Sweden
🇹🇷
Hacettepe University, School of Medicine; Pediatrics Department; Pediatrics Child Neurology Unit, Ankara, Turkey

and more 6 locations

An Observational Study of Patients With Malignant Lymphomas Treated With MabThera® SC in Everyday Clinical Practice

Completed

Conditions: Lymphoma, B-Cell, Lymphoma, Follicular

First Posted Date: 2014-09-15

Last Posted Date: 2020-10-30

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 688

Registration Number: NCT02240316

Locations: 🇩🇪
Universitätsklinikum Essen; Klinik für Hämatologie, Essen, Germany

An Observational Study of Methoxy Polyethylene Glycol-Epoetin Beta (Mircera) in Chronic Kidney Disease Participants on Dialysis

Completed

Conditions: Chronic Kidney Diseases

Interventions: Drug: Methoxy Polyethylene Glycol-Epoetin Beta

First Posted Date: 2014-09-12

Last Posted Date: 2017-05-15

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 197

Registration Number: NCT02238080

Locations: 🇮🇱
Holy Family Hospital; Nephrology, Nazareth, Israel
🇮🇱
Rebecca Sief Hospital; Nephrology, Safed, Israel
🇮🇱
Sourasky MC; Dept. of Nephrology, Tel Aviv, Israel

and more 15 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy